20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Immunovant Inc (IMVT) operates in the BIOTECHNOLOGY industry and is headquartered in Durham, United States with about 315 employees. Its market capitalization is roughly $8 billion. In the fiscal year ended 2026-03-31, IMVT reported $0M in revenue and ($506M) in net income.
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-12-31 | 2018-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $7M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | — | — | — |
| Gross Profit | — | $0M | $0M | $0M | ($1M) | ($1M) | ($1M) | $0M | — | — | — |
| Gross Margin % | — | — | — | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($559M) | ($533M) | ($438M) | ($270M) | ($208M) | ($156M) | ($108M) | ($60M) | $0M | $0M | ($137M) |
| Operating Margin % | -7877.5% | — | — | — | — | — | — | — | — | — | — |
| Net Income | ($538M) | ($506M) | ($414M) | ($259M) | ($211M) | ($157M) | ($107M) | ($66M) | $0M | $0M | ($137M) |
| Net Margin % | -7585.9% | — | — | — | — | — | — | — | — | — | — |
| EBITDA | ($539M) | ($505M) | ($413M) | ($259M) | ($198M) | ($157M) | ($108M) | ($66M) | $0M | — | — |
| Earnings Per Share (EPS) | $-2.81 | $-2.77 | $-2.73 | $-1.88 | $-1.71 | $-1.43 | $-1.22 | $-1.54 | $-0.00 | — | $-13.67 |
| Shares Outstanding (M) | 206M | 182M | 152M | 138M | 123M | 110M | 88M | 43M | 14M | — | 10M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $7M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | $7M | — | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Margin % | 100.0% | — | — | — | — | 50.0% | — | — |
| Operating Income (EBIT) | ($153M) | ($160M) | ($114M) | ($132M) | ($127M) | ($114M) | ($114M) | ($116M) |
| Operating Margin % | -2159.7% | — | — | — | — | -71140.6% | — | — |
| Net Income | ($153M) | ($148M) | ($111M) | ($127M) | ($121M) | ($106M) | ($111M) | ($109M) |
| Net Margin % | -2159.6% | — | — | — | — | -66530.6% | — | — |
| EBITDA | ($153M) | ($151M) | ($109M) | ($126M) | ($120M) | ($106M) | ($111M) | ($109M) |
| Earnings Per Share (EPS) | $-0.75 | $-0.73 | $-0.61 | $-0.73 | $-0.71 | $-0.70 | $-0.76 | $-0.74 |
| Shares Outstanding (M) | 206M | 204M | 182M | 174M | 171M | 152M | 147M | 146M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-12-31 | 2018-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($414M) | ($407M) | ($376M) | ($214M) | ($188M) | ($106M) | ($83M) | ($53M) | ($29M) | — | ($128M) |
| Capital Expenditures (CapEx) | $0M | $0M | $1M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($414M) | ($407M) | ($377M) | ($215M) | ($188M) | ($106M) | ($84M) | ($53M) | ($29M) | — | ($128M) |
| FCF Margin % | -5839.5% | — | — | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($124M) | ($95M) | ($92M) | ($103M) | ($117M) | ($111M) | ($100M) | ($89M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($124M) | ($95M) | ($92M) | ($103M) | ($117M) | ($111M) | ($101M) | ($89M) |
| FCF Margin % | -1753.4% | — | — | — | — | -69273.8% | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $852M | $958M | $776M | $667M | $406M | $516M | $412M | $109M | $0M | $0M |
| Cash & Cash Equivalents | $798M | $902M | $714M | $635M | $377M | $494M | $400M | $101M | $0M | — |
| Total Liabilities | $117M | $105M | $69M | $49M | $43M | $46M | $21M | $15M | $0M | $2M |
| Total Debt (Short + Long-Term) | $0M | $0M | $0M | $0M | $1M | $1M | $1M | $3M | $0M | $0M |
| Total Shareholders' Equity | $735M | $853M | $707M | $618M | $362M | $470M | $391M | $94M | $0M | ($1M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IMVT viewer.
This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी
About TickerBase · Data methodology & sources · Privacy · Terms